Small peptides, derived from endogenous proteins bind within the antigen binding groove created by the 3-pleated sheets and ol helices of the oll and o~2 domains of the class I molecule of the major histocompatibility complex (MHC). However, the precise role of peptide in class I MHC conformation remains unclear. Here, we have shown that, in at least some instances, changes induced in the MHC molecule by the binding of distinct peptides can be identified as specific alterations in serological epitopes expressed on the class I protein. The nature of specific peptides expressed by dass I-bearing cells may, therefore, have a dramatic influence on T cell development, self-tolerance, and alloreactivity.
I
n recent years, tremendous progress has been made in 9 elucidating the molecular aspects of MHC class I-peptide interaction. The structural analyses of crystallized HLA class I molecules have included A2, Aw68, and B27 (1) (2) (3) . In all instances, small peptides have been observed within the cleft formed by the ol helices and ~-pleated sheet constituted by the c~1 and ol2 domains. Recent studies have shown that optimal peptide binding to the murine class I antigen, H-2K b, occurs with small peptides (8) (9) amino acids long, peptides containing a leucine at the COOH terminus, and amino acids with aromatic side chains (phenylalanine or tyrosine) at the 5 th (8 mer) or 6 th (9 met) position (4) (5) (6) . These amino acid residues provide the anchor points for the peptide in the cleft. The recent solution of the x-ray crystal structure of a single MHC class I molecule, H-2K b, occupied by distinct peptides, suggested that these peptides may influence MHC dass I conformation (7) .
We, therefore, examined the role of peptide in MHC conformation using the mutant cell lines RMA-S and T2. These cell lines are class I-deficient somatic variants of RMA (mouse) and B-LCL721 (human) tumor cells due to defects in the transporter proteins, transporter associated with antigen processing (TAP), necessary for providing processed peptides for binding to the newly synthesized class I molecules (8) (9) (10) (11) (12) . The addition of preprocessed antigenic peptides to these mutant cells results in stable assembly and cell surface expression of class I predominantly bound to the added peptide.
In the present experiments, we studied the effects of specific peptides on class I recognition of H-2Kb-specific alloantibodies. The peptide transporter mutants, RMA-S and T2-Kb/D a, were pulsed with various K b binding peptides. Class I molecules bound by the different peptides were distinguishable by mAb binding. These results suggest that, in at least some instances, MHC conformation as detected by serological epitopes may depend on the peptide bound to the class I molecule.
Materials and Methods
Tumors. 
Results and Discussion
To assess class I conformational features, the binding of a panel of mAbs specific for H-2K b was examined on wildtype, RMA, and mutant, RMA-S tumor lines in the absence or presence of distinct exogenous peptides. As seen in However, examination of the relative binding of the different mAbs to RMA-S RT revealed that 100-30 bound proportionally greater than 5F1-2-14 or Y-3, a serological pattern different from that seen on RMA.
The serological profile of K s molecules on RMA-S pulsed with exogenous peptides was also significantly different than RMA. The serology of RMA-S cells pulsed with SV8 NP, SV9 NP, and FLU-NP peptides was similar to the RMA-S RT cells as 5F1-2-14 bound relatively poorly, if at all (SV9 NP), to these cells, and 100-30 reacted strongly. In contrast, K b molecules expressed by RMA-S cells incubated with the OVA peptide or VSV NP peptide reacted strongly with the 5F1-2-14 mAb. In addition, there was virtually no binding of the 100-30 mAb to OVA-pulsed RMA-S cells and weak binding to VSV NP-pulsed RMA-S. The relative differences in the K b reactivity were not due to antibody titer or isotype, as shown in Fig. 2 . All of the antibodies bound at different saturating levels on each cell type. For instance, plateau binding of 5F1-2-14 occurred with a mean fluorescence (MF) of 325 on OVA-pulsed RMA-S cells, but only MF 50 on SV8 NP-pulsed RMA-S. In contrast, 100-30 bound with a MF of 125 and 15 on SV8 NP-and OVA-pulsed RMA-S cells, respectively. The differences in maximal antibody binding, combined with the dramatically different slopes of the titration curves, suggested that the same mAb has different a~nities for the K s molecule associated with different peptides. It is interesting that another mAb, AF6-88.5, whose K b binding was previously reported to be murine/32M dependent (25) , and did not react with human/32M-associated human C1R-K b cells (data not shown), also demonstrated different binding activity on K b molecules loaded with the different peptides. RMA-S cells pulsed with OVA, VSV NP, and SV9 NP bound AF6-88.5 well, whereas RMA-S RT, RMA-S plus SV8 NP, and RMA-S FLU-NP (data not shown) bound it poorly. Therefore, it is likely that the AF6-88.5 binding is dependent on both murine/32M association and peptide-induced class I conformation, perhaps at the site where B2M interacts with the or1 domain of K b (26) .
To determine the absolute binding of the Kb-specific mAbs, T2 cells were transfected with a chimeric Kb/D a construct encoding the c~1 and o~2 domains of K s and the c~3 domain of D d. This chimeric MHC molecule can be identified by an c~3-specific mAb, 34-2-12, that is not influenced by peptide binding. As seen in Fig. 3 a, the pattern of mAb binding varied significantly among the peptidepulsed T2-Kb/D a tumor lines. Anti-H-2D d binding increased equivalently on transfectants pulsed with SV9 and OVA peptides (dashed lines). Furthermore, there was a dramatic difference in the reactivity of 5F1 (solid lines) and 100-30 (dotted lines) between the two peptide-pulsed cell populations. Similar dramatic differences were observed when K bspecific mAb reactivity was normalized to the ot3-specific mAb staining (Fig. 3 b) . Two conclusions can be drawn from this data. First, the staining of peptide-pulsed Kb/Da-transfected T2 cells was remarkably similar to the RMA-S cells cultured with the different peptides. For instance, the absolute binding of 5F1-2-14 was much more ef~dent on OVA-pulsed cells than on SV9 NP cells. In contrast, 100-30 did not bind OVApulsed cells at all, but bound very well to SV9 NP-pulsed cells. In fact, these serological alterations were observed in as little as 1-h incubation with peptide (data not shown). Second, recent studies have shown that the nonamer peptide of the Sendai NP binds 1,000-fold better than the octamer. Yet, with the exception of 5F1-2-14 binding, which was weak on SV8 NP-pulsed RMA-S but nonexistent on SV9 NP-pulsed cells, the mAb binding pattern observed with SV9 and SV8 NP was similar, whereas mAb-binding to SV8 NP-and OVApulsed cells was quite dissimilar. Thus, the differences in serology of the K b molecule loaded with different peptides did not correlate with peptide length or affinity. A dose titration of OVA peptide on T2-Kb/D d showed that overnight incubation with as little as 10-3-10 -4/~g/ml of OVA peptide resulted in a diminution of 100-30 mAb binding and a concomitant increase in 5F1-2-14 binding (Fig.  4 a) . A more detailed analysis of the influence of the OVA peptide on K b serology was performed using OVA peptides in which individual amino acids were substituted with alanine residues. As illustrated in Fig. 4 b, OVA peptides containing substituted alanines at positions 261 or 264 did not increase K b expression. In previous studies by Falk et al. (4, 27) , residues 5 (amino acid 261) and 8 (amino acid 264) were shown to be critical residues for peptide binding to K b. Thus, it is not surprising that these alanine substitutions affected MHC binding. In contrast, significant increases in H-2K b expression was observed with all other alaninesubstituted peptides. The reactivity of four different mAbs on OVA-pulsed RMA-S cells was not significantly effected by several individual alanine substitutions including: OVA peptide-serine 257 --* alanine 257 (OVA-S257A), OVA-I258A, OVA-N260A, or OVA-E262A. However, substitution of the isoleucine 259 with an alanine resulted in diminished AF6.88-5 staining and increased 100-30 staining. Residue 259 is thought to be an MHC contact residue (5, 7). Therefore, substitution of an isoleucine with an alanine may alter peptide-MHC contact.
One implication of the serological analysis of the alaninesubstituted peptide is that, in addition to direct effects of peptide binding, there may be allosteric effects as well. Several years ago, in collaboration with Ajitkumar et al., we demonstrated that single point mutations in amino acids 162 or 166 of the oc2 domain had profound effects on the 5F1-2-14 epitope (28) . Based on recent crystal structure analyses, the NH2-terminal residues of the peptide localize near these amino acids. These observations suggest that many of the serological changes observed using different peptides depend on the NHz-terminal residues of the peptide which vary substantially among OVA, VSV NP, and SV NP. In fact, the difference in 5F1-2-14 binding between SV8 NP and SV9 NP is a direct result of the NH2-terminal phenylalanine. However, we also observed that a single amino acid change in residue 7 of the OVA peptide (OVA-K263A) decreased 5F1-2-14 binding (Fig. 4 b) , suggesting possible aUosteric effects on mAb binding.
In conclusion, the data cannot easily distinguish whether the serological changes observed result solely from conformational changes in the ce helices or associated side chains, or from the steric effects ofpeptide binding. The 100-30 and 5F1-2-14 epitopes have totally distinct patterns of binding. This does not appear to be a steric effect of peptide binding since 5F1-2-14 does not effectively bind to "empty" K b molecules (Fig. 3) . By comparison, the 100-30 mAb binds effectively to empty K b and SV-pulsed K b, but not OVA-pulsed K b. More importantly, recent x-ray crystallographic studies by Fremont et al. (7) illustrate the potential conformation changes that result from the binding of different peptides to the same MHC class I molecule.
Finally, the likelihood that class I MHC molecules can exist in different conformations on the cell surface has profound implications for aUorecognition. Although a number of studies have suggested that many aUoreactive cells are peptide specific, recent studies by several groups support the idea that some alloreactive clones recognize MHC conformational epitopes, since some of the alloreactive CTL examined recognized peptides present in several distinct peptide peaks after HPLC separation of peptides eluted from class I MHC, "naked" MHC (29, 30) , or class I loaded with distinct peptides (31; and Bluestone, J. A., S. Jameson, K. Arunan, and R. Dick II, manuscript in preparation). These results support the notion that at least some alloreactive T cells recognize class I in a peptidedependent but not peptide-specific manner, and that the nature of the peptide that occupies the MHC groove can alter allorecognition of foreign class I MHC. If, indeed, the nature of the peptide within the MHC cleft can influence TCR recognition, then subtle peptide-driven changes in MHC structure would impact not only on antigen-specific responses, but also on T cell development, self-tolerance to tissue-specific antigens, and alloreactivity.
